Linda Bammann files Form 4: 9,500 JPM shares sold under 10b5-1 plan
Rhea-AI Filing Summary
Insider sale reported by Linda Bammann, a director of JPMorgan Chase & Co. On 09/02/2025 she sold 9,500 shares of JPMorgan common stock at $297.9444 per share under a Rule 10b5-1 plan, reducing her beneficial ownership to 82,207.3407 shares. The Form 4 was signed under power of attorney by Holly Youngwood on 09/02/2025.
Positive
- Transaction executed under a Rule 10b5-1 plan, indicating a prearranged trading plan that can provide an affirmative defense
- Timely disclosure filed on the same date as the transaction (09/02/2025) and signed under POA
Negative
- Reduction in director's beneficial ownership by 9,500 shares to 82,207.3407 shares
- No additional context provided in this filing about the reason for the sale or the 10b5-1 plan adoption date
Insights
TL;DR: Routine, prearranged director sale under a 10b5-1 plan; complies with reporting rules and reduces director stake modestly.
This transaction is a typical Section 16 disclosure of an insider sale executed pursuant to a 10b5-1 trading plan, which provides an affirmative defense against insider trading claims when properly adopted. The sale of 9,500 shares at $297.9444 reduces reported beneficial ownership to 82,207.3407 shares. There is no derivative activity reported and no amendment noted. For governance scrutiny, key points are the presence of a 10b5-1 plan and timely reporting.
TL;DR: Non-material in isolation for JPMorgan; routine disclosure with clear price and post-transaction holdings.
The Form 4 shows a straightforward disposition by a director rather than company-wide programmatic activity. The transaction size (9,500 shares) should be evaluated relative to the director's total holdings and typical trading patterns, but on its face it is a routine reduction of beneficial ownership without associated derivative transactions or additional context in this filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 9,500 | $297.9444 | $2.83M |
AI-generated analysis. How Rhea-AI works. Not financial advice.